S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.84 (-5.01%)
AAPL   140.65 (-5.76%)
MSFT   253.95 (-4.82%)
FB   192.24 (-5.12%)
GOOGL   2,237.00 (-3.97%)
AMZN   2,141.77 (-7.18%)
TSLA   708.00 (-7.04%)
NVDA   168.98 (-7.04%)
BABA   87.35 (-5.04%)
NIO   15.86 (-4.63%)
AMD   96.21 (-6.11%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.79 (-5.47%)
DIS   104.33 (-3.97%)
AMC   12.80 (-0.78%)
PFE   50.41 (-1.81%)
PYPL   77.19 (-3.21%)
NFLX   177.18 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.84 (-5.01%)
AAPL   140.65 (-5.76%)
MSFT   253.95 (-4.82%)
FB   192.24 (-5.12%)
GOOGL   2,237.00 (-3.97%)
AMZN   2,141.77 (-7.18%)
TSLA   708.00 (-7.04%)
NVDA   168.98 (-7.04%)
BABA   87.35 (-5.04%)
NIO   15.86 (-4.63%)
AMD   96.21 (-6.11%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.79 (-5.47%)
DIS   104.33 (-3.97%)
AMC   12.80 (-0.78%)
PFE   50.41 (-1.81%)
PYPL   77.19 (-3.21%)
NFLX   177.18 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.84 (-5.01%)
AAPL   140.65 (-5.76%)
MSFT   253.95 (-4.82%)
FB   192.24 (-5.12%)
GOOGL   2,237.00 (-3.97%)
AMZN   2,141.77 (-7.18%)
TSLA   708.00 (-7.04%)
NVDA   168.98 (-7.04%)
BABA   87.35 (-5.04%)
NIO   15.86 (-4.63%)
AMD   96.21 (-6.11%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.79 (-5.47%)
DIS   104.33 (-3.97%)
AMC   12.80 (-0.78%)
PFE   50.41 (-1.81%)
PYPL   77.19 (-3.21%)
NFLX   177.18 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   290.84 (-5.01%)
AAPL   140.65 (-5.76%)
MSFT   253.95 (-4.82%)
FB   192.24 (-5.12%)
GOOGL   2,237.00 (-3.97%)
AMZN   2,141.77 (-7.18%)
TSLA   708.00 (-7.04%)
NVDA   168.98 (-7.04%)
BABA   87.35 (-5.04%)
NIO   15.86 (-4.63%)
AMD   96.21 (-6.11%)
CGC   5.59 (-5.09%)
MU   71.05 (-4.61%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.79 (-5.47%)
DIS   104.33 (-3.97%)
AMC   12.80 (-0.78%)
PFE   50.41 (-1.81%)
PYPL   77.19 (-3.21%)
NFLX   177.18 (-7.02%)
OTCMKTS:AVCTF

Avacta Group (AVCTF) Stock Forecast, Price & News

$0.77
0.00 (0.00%)
(As of 05/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.77
$0.77
50-Day Range
$0.77
$0.97
52-Week Range
$0.77
$3.50
Volume
N/A
Average Volume
917 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive AVCTF News and Ratings via Email

Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter.

Avacta Group logo

About Avacta Group

Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe. It operates in three segments: Diagnostics, Therapeutics, and Animal Health. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops novel cancer immunotherapies combining proprietary platforms; and provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The company has a research partnership with Moderna Therapeutics; research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein; co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies; drug development collaboration with LG Chem Life Sciences; a partnership with Selexis to develop cell line for clinical manufacturing, and with Tufts University School of Medicine for developing Affimer drug conjugate therapies; a collaboration with Cytiva to develop and manufacture an Affimer-based point-of-care rapid test; and a collaboration with Adeptrix to develop Affimer-based COVID-19 antigen tests. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Miscellaneous Commercial Services
Sub-Industry
N/A
Current Symbol
OTCMKTS:AVCTF
CIK
N/A
Fax
N/A
Employees
123
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Avacta Group (OTCMKTS:AVCTF) Frequently Asked Questions

Who are Avacta Group's key executives?
Avacta Group's management team includes the following people:
  • Dr. David Alastair Smith, CEO & Exec. Director
  • Mr. Tony Gardiner, CFO, Company Sec. & Exec. Director (Age 51, Pay $248.33k)
  • Ms. Emma Wright, Group In-House Counsel
  • Mr. Michael Vinegrad, Group Communications Director
  • Dr. Matt Johnson, Chief Scientific Officer of Diagnostics
  • Dr. Neil Bell, Chief Devel. Officer of Therapeutics (Age 64)
  • Dr. Fiona McLaughlin FSB, Ph.D., Chief Scientific Officer of Therapeutics Division (Age 52)
  • Mr. Marc Green, Head of Product Devel. - Diagnostics
  • Gemma Wilson, Head of QA/RA - Diagnostics
  • Mr. Petros Sarantos, Head of Product Management - Diagnostics
What is Avacta Group's stock symbol?

Avacta Group trades on the OTCMKTS under the ticker symbol "AVCTF."

How do I buy shares of Avacta Group?

Shares of AVCTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avacta Group's stock price today?

One share of AVCTF stock can currently be purchased for approximately $0.77.

How many employees does Avacta Group have?

Avacta Group employs 123 workers across the globe.

What is Avacta Group's official website?

The official website for Avacta Group is www.avacta.com.

How can I contact Avacta Group?

Avacta Group's mailing address is Thorp Arch Estate, Leeds, West Yorkshire. The company can be reached via phone at 44.1904.21.7070.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.